EARLY TUMOR VOLUME EVOLUTION ADAPTIVELY PREDICTS PATIENT-SPECIFIC RESPONSE AND PROGRESSION RISK TO RADIOTHERAPY, PEMBROLIZUMAB, AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA IN A PHASE I TRIAL

被引：0
|
作者：
Glazar, Daniel [1 ]
Brady, Rene [1 ]
Howard, Rachel [1 ]
Grass, Daniel [1 ]
Arrington, John [1 ]
Yu, Michael [1 ]
Raghunand, Natarajan [1 ]
Sahebjam, Solmaz [1 ]
Enderling, Heiko [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
NEURO-ONCOLOGY | 2019年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
COMP-13
引用
收藏
页码：63 / 64
页数：2
相关论文
共 7 条
  • [1] Tumor Volume Dynamics as an Early Biomarker for Patient-Specific Evolution of Resistance and Progression in Recurrent High-Grade Glioma
    Glazar, Daniel J.
    Grass, G. Daniel
    Arrington, John A.
    Forsyth, Peter A.
    Raghunand, Natarajan
    Yu, Hsiang-Hsuan Michael
    Sahebjam, Solmaz
    Enderling, Heiko
    [J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (07) : 1 - 11
  • [2] A phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG).
    Drappatz, J.
    Raizer, J. J.
    Schiff, D.
    Chi, A. S.
    Batchelor, T.
    Snodgrass, S. M.
    Quant, E. C.
    Norden, A. D.
    Beroukhim, R.
    Grimm, S. A.
    Doherty, L. M.
    Ciampa, A. S.
    LaFrankie, D. C.
    Ruland, S.
    Gerard, M.
    Hammond, S.
    Wen, P. Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] VORINOSTAT, BEVACIZUMAB, AND METRONOMIC TEMOZOLOMIDE FOR RECURRENT HIGH-GRADE GLIOMA: A PHASE I/II CLINICAL TRIAL
    Peters, Katherine B.
    Reardon, David A.
    Vredenburgh, James J.
    Desjardins, Annick
    Herndon, James E., II
    Coan, April
    McSherry, Frances
    Lipp, Eric
    Brickhouse, Alise
    Massey, Woody
    Friedman, Henry S.
    [J]. NEURO-ONCOLOGY, 2012, 14 : 81 - 81
  • [4] MRI AND FET PET FOR RADIOTHERAPY PLANNING IN RECURRENT HIGH-GRADE GLIOMA (HGG) IN A PROSPECTIVE PHASE I TRIAL
    Moller, Soren
    Lundemann, Michael
    af Rosenschold, Per Munck
    Costa, Junia
    Engelholm, Silke
    Law, Ian
    Poulsen, Hans Skovgaard
    Engelholm, Svend Aage
    [J]. NEURO-ONCOLOGY, 2014, 16
  • [5] A PHASE I TRIAL OF HYPOFRACTIONATED STEREOTACTIC IRRADIATION (HFSRT) WITH PEMBROLIZUMAB AND BEVACIZUMAB IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA (NCT02313272)
    Sahebjam, Solmaz
    Forsyth, Peter
    Arrington, John
    Jaglal, Michael
    Tran, Nam D.
    Etame, Arnold B.
    Wicklund, Melissa
    Drury-Sibiga, Ali
    Long, Wendy
    Evernden, Brittany
    Gatewood, Tyra
    Macaulay, Robert
    Chinnaiyan, Prakash
    Yu, Michael
    [J]. NEURO-ONCOLOGY, 2017, 19 : 30 - 30
  • [6] A PHASE I TRIAL OF TUMOR TREATING FIELDS WITH AND WITHOUT CONCOMITANT TEMOZOLOMIDE AND BEVACIZUMAB IN PEDIATRIC PATIENTS WITH HIGH-GRADE GLIOMA AND EPENDYMOMA
    Hanson, Derek
    [J]. NEURO-ONCOLOGY, 2018, 20 : 202 - 203
  • [7] Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience
    Hou, Ming-Mo
    Wang, Zhijie
    Janku, Filip
    Piha-Paul, Sarina
    Naing, Aung
    Hong, David
    Westin, Shannon
    Coleman, Robert L.
    Sood, Anil K.
    Tsimberidou, Apostolia M.
    Subbiah, Vivek
    Wheler, Jennifer
    Zinner, Ralph
    Lu, Karen
    Meric-Bernstam, Funda
    Fu, Siqing
    [J]. ONCOTARGET, 2016, 7 (23) : 35132 - 35143
1